ClinicalTrials.gg
CompletedNCT01681186Updated Oct 21, 2019Results posted

A Study of LY2940680 in Healthy Participants

A Phase 1 interventional study of LY2940680 Capsule(s) (Reference) and LY2940680 Tablet (Test) in Healthy Participants, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-21.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants. Part A will involve two groups of participants, each taking up to two single doses of LY2940680 at different dose levels. There is a minimum 14 day washout period between each of the participant's doses. The purpose of Part B is to study how much of the study drug, in capsule or tablet form, gets into the bloodstream and how long the body takes to get rid of it. In addition, the effect of food and a proton pump inhibitor (PPI) on LY2940680 will be studied. Part B will involve one group of participants who will take four single doses of 100 milligrams (mg) LY2940680. There is a minimum 7 day washout period between doses. Participants may only enroll in one part. Screening is required within 28 days prior to the start of the study.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy sterile males or surgically sterile females or females, as determined by medical history and physical examination
  • of 18.5 to 32.0 kilograms per meter square (kg/m\^2)
  • Have clinical laboratory test results within normal reference range
  • Have given written approved by Lilly and the ethical review board (ERB) governing the site
  • Prepared to eat an entire high fat breakfast

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, have completed or discontinued within the last 30 days from a clinical trial involving an product
  • Have known allergies to LY2940680, related compounds or any components of the formulation, or known allergies to lansoprazole (Part B only)
  • Have previously completed or withdrawn from this study or any other study investigating LY2940680, and have previously received the investigational product. Participants in Part A are not allowed to participate in Part B
  • Have an abnormality in the 12-lead (ECG)
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data (cholecystectomy or appendectomy are allowed if surgery at least 6 months prior to screening)
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Show evidence of and/or positive hepatitis B surface antigen
  • Have used or intend to use over-the-counter or prescription medication within 14 days prior to dosing or during the study. Exception: participants may continue hormone replacement therapy (HRT; estrogen)
  • Use of herbal supplements, grapefruit juice, grapefruits, Seville orange juice, Seville oranges, or Starfruit within 7 days prior to dosing or during the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    LY2940680 (Part A)

    Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods

    Drug: LY2940680 Capsule(s) (Reference)

  • Placebo comparator
    Placebo (Part A)

    Placebo given once orally in up to 1 of 2 study periods

    Drug: Placebo Capsule(s)

  • Experimental
    LY2940680 Capsule Fasted (Part B)

    100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods

    Drug: LY2940680 Capsule(s) (Reference)

  • Experimental
    LY2940680 Tablet Fasted (Part B)

    100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods

    Drug: LY2940680 Tablet (Test)

  • Experimental
    LY2940680 Tablet Fed (Part B)

    100 mg LY2940680 given once orally as a tablet (test formulation) in fed state following a standardized, high-fat breakfast in 1 of 4 study periods

    Drug: LY2940680 Tablet (Test)

  • Experimental
    LY2940680 Tablet Fasted + PPI (Part B)

    30 mg lansoprazole (PPI) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods

    Drug: LY2940680 Tablet (Test) · Drug: Lansoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs

    Data presented are the number of participants with AEs or any serious AEs (SAEs) regardless of causality. A summary of non-serious AEs is located in the Reported Adverse Events section.

    Time frame: Baseline through study completion (up to 4 weeks in Part A and 8 weeks in Part B)

  2. Part B: Pharmacokinetics: Maximum Observed Concentrations (Cmax) of LY2940680 Test and Reference Formulation

    The Cmax of 100-milligram (mg) LY2940680 capsule (reference formulation) and 100-mg LY2940680 tablet (test formulation) in fasted and fed state, and with lansoprazole during Part B of the study.

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours after administration of study drug

Secondary outcomes

  1. Part A: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax)

    The Cmax of LY2940680 during Part A of the study was reported.

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug

  2. Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)

    Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug

  3. Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)

    Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug

  4. Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]

    Part A: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration \[AUC(0-tlast)\]

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug

  5. Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]

    Part B: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration \[AUC(0-tlast)\]

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug

  6. Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]

    Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity \[AUC(0-∞)\]

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug

  7. Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]

    Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity \[AUC(0-∞)\]

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug

07

Results

Posted Oct 21, 2019

Participant flow

First Intervention
Participant flow — First Intervention
MilestonePart A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2
Started42233277
Completed42233277
Not completed00000000
Washout Period From First Intervention
Participant flow — Washout Period From First Intervention
MilestonePart A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2
Started42233277
Completed42233277
Not completed00000000
Second Intervention
Participant flow — Second Intervention
MilestonePart A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2
Started42233277
Completed42233277
Not completed00000000
Washout Period From Second Intervention
Participant flow — Washout Period From Second Intervention
MilestonePart A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2
Started00000077
Completed00000066
Not completed00000011
Withdrew: Adverse event00000010
Withdrew: Protocol violation00000001
Third Intervention
Participant flow — Third Intervention
MilestonePart A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2
Started00000066
Completed00000066
Not completed00000000
Washout Period From Third Intervention
Participant flow — Washout Period From Third Intervention
MilestonePart A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2
Started00000066
Completed00000056
Not completed00000010
Withdrew: Lost to follow-up00000010
Fourth Intervention
Participant flow — Fourth Intervention
MilestonePart A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2
Started00000056
Completed00000055
Not completed00000001
Withdrew: Protocol violation00000001

Outcome measures

PrimaryNumber of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs

Data presented are the number of participants with AEs or any serious AEs (SAEs) regardless of causality. A summary of non-serious AEs is located in the Reported Adverse Events section.

Time frame:
Baseline through study completion (up to 4 weeks in Part A and 8 weeks in Part B)
Reported as:
Count of participants · Participants
Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs
ParticipantsPlacebo Capsule (Fasted)50-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Capsule (Fasted) Part A100-mg LY2940680 Capsule (Fasted) Part B100-mg LY2940680 Tablet (Fasted)100-mg LY2940680 Tablet Plus 30-mg Lansoprazole (Fasted)100-mg LY2940680 Tablet (Fed)200-mg LY2940680 Capsule (Fasted)400-mg LY2940680 Capsule (Fasted)
Adverse Events (AEs)234653533
Serious Adverse Events (SAEs)000000000
PrimaryPart B: Pharmacokinetics: Maximum Observed Concentrations (Cmax) of LY2940680 Test and Reference Formulation

The Cmax of 100-milligram (mg) LY2940680 capsule (reference formulation) and 100-mg LY2940680 tablet (test formulation) in fasted and fed state, and with lansoprazole during Part B of the study.

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours after administration of study drug
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Part B: Pharmacokinetics: Maximum Observed Concentrations (Cmax) of LY2940680 Test and Reference Formulation
nanograms per milliliter (ng/mL)100-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Tablet (Fasted)100-mg LY2940680 Tablet (Fed)100-mg LY2940680 Tablet Plus 30-mg Lansoprazole (Fasted)
Part B: Pharmacokinetics: Maximum Observed Concentrations (Cmax) of LY2940680 Test and Reference Formulation879 ± 49.31170 ± 22.4776 ± 26.31290 ± 47.9
SecondaryPart A: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax)

The Cmax of LY2940680 during Part A of the study was reported.

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Part A: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax)
nanograms per milliliter (ng/mL)50-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Capsule (Fasted)200-mg LY2940680 Capsule (Fasted)400-mg LY2940680 Capsule (Fasted)
Part A: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax)622 ± 25.3661 ± 68.31740 ± 15.63360 ± 32.8
SecondaryPart A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)

Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Reported as:
Median · hours (h)
Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)
hours (h)50-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Capsule (Fasted)200-mg LY2940680 Capsule (Fasted)400-mg LY2940680 Capsule (Fasted)
Part A: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)1.5 (0.92 to 3.0)2 (2.0 to 4.03)2 (1.0 to 2.0)2 (1.0 to 3.0)
SecondaryPart B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)

Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (tmax)

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug
Reported as:
Median · hours (h)
Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)
hours (h)100-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Tablet (Fasted)100-mg LY2940680 Tablet (Fed)100-mg LY2940680 Tablet (Fasted) PPI
Part B: Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax)1 (1 to 4)1.5 (1 to 4)3 (2 to 8)1 (1 to 3)
SecondaryPart A: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]

Part A: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration \[AUC(0-tlast)\]

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Reported as:
Geometric mean · nanograms*hours per milliliter (ng*h/mL)
Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]
nanograms*hours per milliliter (ng*h/mL)50-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Capsule (Fasted)200-mg LY2940680 Capsule (Fasted)400-mg LY2940680 Capsule (Fasted)
Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]5300 ± 27.59440 ± 53.922800 ± 21.249300 ± 27.9
SecondaryPart B: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]

Part B: Pharmacokinetics: Area Under the Curve from Time Zero to Time T, where T is the Last Time Point with a Measurable Concentration \[AUC(0-tlast)\]

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug
Reported as:
Geometric mean · nanograms*hours per milliliter (ng*h/mL)
Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]
nanograms*hours per milliliter (ng*h/mL)100-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Tablet (Fasted)100-mg LY2940680 Tablet (Fed)100-mg LY2940680 Tablet (Fasted) PPI
Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [AUC(0-tlast)]9390 ± 41.110300 ± 39.911200 ± 37.29980 ± 50.1
SecondaryPart A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]

Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity \[AUC(0-∞)\]

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, and 120 hours after administration of study drug
Reported as:
Geometric mean · nanograms*hours per milliliter (ng*h/mL)
Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]
nanograms*hours per milliliter (ng*h/mL)50-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Capsule (Fasted)200-mg LY2940680 Capsule (Fasted)400-mg LY2940680 Capsule (Fasted)
Part A: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]5340 ± 27.49530 ± 54.023000 ± 21.649800 ± 28.3
SecondaryPart B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]

Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity \[AUC(0-∞)\]

Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hours after administration of study drug
Reported as:
Geometric mean · nanograms*hours per milliliter (ng*h/mL)
Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]
nanograms*hours per milliliter (ng*h/mL)100-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Tablet (Fasted)100-mg LY2940680 Tablet (Fed)100-mg LY2940680 Tablet (Fasted) PPI
Part B: Pharmacokinetics: Area Under the Curve From Time Zero to Infinity [AUC(0-∞)]9460 ± 41.310300 ± 40.111300 ± 37.310000 ± 50.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Capsule (Fasted)—0/9 (0%)2/9 (22.2%)
50-mg LY2940680 Capsule (Fasted)—0/6 (0%)3/6 (50%)
100-mg LY2940680 Capsule (Fasted) Part A or Part B—0/20 (0%)10/20 (50%)
100 mg LY2940680 Tablet (Fasted)—0/14 (0%)5/14 (35.7%)
100-mg LY2940680 Tablet Plus 30-mg Lansoprazole (Fasted)—0/11 (0%)3/11 (27.3%)
100-mg LY2940680 Tablet (Fed)—0/12 (0%)5/12 (41.7%)
200-mg LY2940680 Capsule (Fasted)—0/6 (0%)3/6 (50%)
400-mg LY2940680 Capsule (Fasted)—0/5 (0%)3/5 (60%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlacebo Capsule (Fasted)50-mg LY2940680 Capsule (Fasted)100-mg LY2940680 Capsule (Fasted) Part A or Part B100 mg LY2940680 Tablet (Fasted)100-mg LY2940680 Tablet Plus 30-mg Lansoprazole (Fasted)100-mg LY2940680 Tablet (Fed)200-mg LY2940680 Capsule (Fasted)400-mg LY2940680 Capsule (Fasted)
HeadacheNervous system disorders2/91/66/203/140/113/123/61/5
Muscle spasmsMusculoskeletal and connective tissue disorders0/90/60/200/140/110/120/62/5
NauseaGastrointestinal disorders1/91/62/200/140/111/122/60/5
Nasal congestionRespiratory, thoracic and mediastinal disorders0/91/61/200/140/110/120/61/5
ParaesthesiaNervous system disorders0/90/60/200/140/110/121/60/5
FlushingVascular disorders0/91/60/200/140/110/120/60/5
DizzinessNervous system disorders0/90/63/200/140/110/120/60/5
VomitingGastrointestinal disorders0/90/62/200/141/111/120/60/5
Facial painGeneral disorders0/90/60/200/141/110/120/60/5
PainGeneral disorders0/90/60/200/141/110/120/60/5

Baseline characteristics

All randomized participants in Part A and B of the study.

Age, Categorical
Age, Categorical(Participants)Part A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2Total
<=18 years000000000
Between 18 and 65 years4223327730
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2Total
Female4222317728
Male000101002
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2Total
Hispanic or Latino0001014410
Not Hispanic or Latino4222313320
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2Total
American Indian or Alaska Native000000000
Asian100000001
Native Hawaiian or Other Pacific Islander000100001
Black or African American010020227
White3122125521
More than one race000000000
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(Participants)Part A, Cohort 1, Sequence 1Part A, Cohort 1, Sequence 2Part A, Cohort 1, Sequence 3Part A, Cohort 2, Sequence 4Part A, Cohort 2, Sequence 5Part A, Cohort 2, Sequence 6Part B, Cohort 3, Sequence 1Part B, Cohort 3, Sequence 2Total
United States4223327730
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2012
First posted
Sep 7, 2012
Start
Sep 2012
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Oct 21, 2019
Last update
Oct 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01681186
Responsible party
Sponsor
First posted
Sep 7, 2012
Start date
Sep 2012
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Oct 21, 2019
Last update
Oct 21, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion